サマリー

米国の人工多能性幹細胞（iPSC）市場は、2023年の2億187万米ドルから2031年には4億8842万米ドルに達し、2024年から2031年の予測期間において年平均成長率10.7％で成長すると予測されている。

市場セグメンテーション
米国人工多能性幹細胞（iPSC）市場：モデルタイプ別（ECMパターン化PAA/PDMS基板、微細溝PDMS基板、歪膜、3Dサコフォールド、自由浮遊ハイドロゲル構造、EHTS）、材料別（天然ハイドロゲルベースの心臓モデル、合成繊維性心臓モデル）、細胞源別（皮膚細胞、血液細胞）、次元タイプ別（2D、3D）、用途（心筋梗塞やその他の疾患によって破壊された組織を置き換えるための新しい心臓組織の作製、心不全、虚血性心疾患、不整脈、心筋症、心臓弁膜症、心臓疾患スクリーニング、その他）、最終用途（製薬・バイオテクノロジー企業、学術・政府研究機関、開発・製造受託機関、その他）、流通チャネル（直接入札、小売販売）、国（米国）-産業動向米国） - 2031年までの産業動向と予測

米国の人工多能性幹細胞（iPSC）市場ダイナミクスの概要

ドライバー

- 再生医療技術の進歩
抑制要因

- 安全性への懸念と技術的困難

機会

- 個別化医療への関心の高まり

市場プレイヤー

米国の人工多能性幹細胞（iPSC）市場で事業を展開している主な市場プレーヤーには、以下のような企業がある：

- コーニング・インコーポレイテッド
- ロンザ
- MIMETAS
- CNバイオ・イノベーションズ
- 3Dバイオテック
- アクソル
- リプロセル社

ページTOPに戻る

目次

TABLE OF CONTENTS
1 INTRODUCTION 11
1.1 OBJECTIVES OF THE STUDY 11
1.2 MARKET DEFINITION 11
1.3 OVERVIEW OF U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET 11
1.4 CURRENCY AND PRICING 12
1.5 LIMITATIONS 12
1.6 MARKETS COVERED 13
2 MARKET SEGMENTATION 15
2.1 MARKETS COVERED 15
2.2 YEARS CONSIDERED FOR THE STUDY 16
2.3 DBMR TRIPOD DATA VALIDATION MODEL 17
2.4 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 20
2.5 DBMR MARKET POSITION GRID 21
2.6 MULTIVARIATE MODELLING 22
2.7 TYPE LIFELINE CURVE 23
2.8 MARKET END USER COVERAGE GRID 24
2.9 SECONDARY SOURCES 25
2.10 ASSUMPTIONS 25
3 EXECUTIVE SUMMARY 26
4 PREMIUM INSIGHTS 29
4.1 PESTEL ANALYSIS 30
4.2 PORTER’S FIVE FORCES 31
5 MARKET OVERVIEW 32
5.1 DRIVERS 34
5.1.1 TECHNOLOGICAL ADVANCEMENT IN REGENERATIVE MEDICINE 34
5.1.2 EXPANDING APPLICATIONS IN DRUGS DISCOVERY 34
5.2 RESTRAINTS 35
5.2.1 SAFETY CONCERNS AND TECHNICAL DIFFICULTIES 35
5.2.2 COMPETITION AND INTELLECTUAL PROPERTY ISSUES 36
5.3 OPPORTUNITIES 36
5.3.1 INCREASING INTEREST OF PERSONALIZED MEDICINE 36
5.3.2 INCREASING ADOPTION OF STEM CELL THERAPY 37
5.4 CHALLENGE 38
5.4.1 HIGH COST ASSOCIATED WITH STEM CELL THERAPIES 38
 
6 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY MODEL TYPE 39
6.1 OVERVIEW 40
6.2 ECM PATTERNED PAA/PDMS SUBSTRATES 43
6.3 MICROGROOVE PDMS SUBSTRATES 43
6.4 STRAINED MEMBRANES 43
6.5 3D SACFFOLDS 43
6.6 FREE-FLOATING HYDROGEL CONTRUCTS 43
6.7 EHTS 43
7 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY MATERIAL 44
7.1 OVERVIEW 45
7.2 NATURAL HYDROGEL- BASED CARDIAC MODELS 48
7.3 SYNTHETICS FIBROUS CARDIAC MODELS 48
7.3.1 POLYGLYCOLIC ACID (PGA) 48
7.3.2 POLY E-CAPROLACTONE (PCL) 48
7.3.3 POLYURETHANE 48
7.3.4 POLYLACTIC ACID (PLA) 49
7.3.5 OTHERS 49
8 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE 50
8.1 OVERVIEW 51
8.2 SKIN CELLS 54
8.2.1 FIBROBLAST 54
8.2.2 KERATINOCYTES 54
8.2.3 MELANOCYTES 54
8.2.4 NEURAL STEM CELLS 54
8.2.5 ADIPOSE DERIVE STEM CELLS 54
8.2.6 OTHERS 55
8.3 BLOOD CELLS 55
8.3.1 PERIPHERAL BLOOD MONOCLEAR CELLS 55
8.3.2 CORD BLOOD ENDOTHELIAL CELLS 55
8.3.3 CORD BLOOD STEM CELLS 55
8.3.4 OTHERS 55
9 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DIMENSIONAL TYPE 56
9.1 OVERVIEW 57
9.2 3D 60
9.3 SKIN CELLS 60
9.3.1 FIBROBLAST 60
9.3.2 KERATINOCYTES 61
9.3.3 MELANOCYTES 61
9.3.4 NEURAL STEM CELLS 61
9.3.5 ADIPOSE DERIVE STEM CELLS 61
9.3.6 OTHERS 61
9.4 BLOOD CELLS 61
9.4.1 PERIPHERAL BLOOD MONOCLEAR CELLS 62
9.4.2 CORD BLOOD ENDOTHELIAL CELLS 62
9.4.3 CORD BLOOD STEM CELLS 62
9.4.4 OTHERS 62
9.5 2D 62
9.5.1 SKIN CELLS 62
9.5.1.1 FIBROBLAST 63
9.5.1.2 KERATINOCYTES 63
9.5.1.3 MELANOCYTES 63
9.5.1.4 NEURAL STEM CELLS 63
9.5.1.5 ADIPOSE DERIVE STEM CELLS 63
9.5.1.6 OTHERS 63
9.5.2 BLOOD CELLS 64
9.5.2.1 PERIPHERAL BLOOD MONOCLEAR CELLS 64
9.5.2.2 CORD BLOOD ENDOTHELIAL CELLS 64
9.5.2.3 CORD BLOOD STEM CELLS 64
9.5.2.4 OTHERS 64
10 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION 65
10.1 OVERVIEW 66
10.2 PRODUCTION OF NEW CARDIAC TISSUE TO REPLACE TISSUES DESTROYED BY INFRACTION OR OTHER DISEASES 70
10.3 HEART FAILURE 70
10.4 ISCHEMIC HEART DISEASE 70
10.5 ARRYTHMIA 70
10.6 CARDIOMYOPATHIES 70
10.7 VALVULAR HEART DISEASE 70
10.8 HEART DISEASE SCREENING 70
10.9 OTHERS 70
11 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USE 71
11.1 OVERVIEW 72
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 75
11.3 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES 75
11.4 CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS 75
11.5 OTHERS 75
12 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL 76
12.1 OVERVIEW 77
12.2 DIRECT TENDER 80
12.3 RETAIL SALES 80
13 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY LANDSCAPE 81
13.1 COMPANY SHARE ANALYSIS: U.S. 81
14 SWOT ANALYSIS 82
15 COMPANY PROFILE 83
15.1 CORNING INCRPORATED 83
15.1.1 COMPANY SNAPSHOT 83
15.1.2 REVENUE ANALYSIS 83
15.1.3 PRODUCT PORTFOLIO 84
15.1.4 RECENT DEVELOPMENT 85
15.2 LONZA 86
15.2.1 COMPANY SNAPSHOT 86
15.2.2 REVENUE ANALYSIS 86
15.2.3 PRODUCT PORTFOLIO 87
15.2.4 RECENT DEVELOPMENT 88
15.3 MIMETAS 89
15.3.1 COMPANY SNAPSHOT 89
15.3.2 PRODUCT PORTFOLIO 89
15.3.3 RECENT DEVELOPMENT 89
15.4 REPROCELL INC. 90
15.4.1 COMPANY SNAPSHOT 90
15.4.2 PRODUCT PORTFOLIO 90
15.4.3 RECENT DEVELOPMENT 91
15.5 CN BIO INNOVATIONS 92
15.5.1 COMPANY SNAPSHOT 92
15.5.2 PRODUCT PORTFOLIO 92
15.5.3 RECENT DEVELOPMENT 93
15.6 AXOL BIOSCIENCE LTD. 94
15.6.1 COMPANY SNAPSHOT 94
15.6.2 PRODUCT PORTFOLIO 94
15.6.3 RECENT DEVELOPMENT 94
15.7 3D BIOTEK LLC. 95
15.7.1 COMPANY SNAPSHOT 95
15.7.2 PRODUCT PORTFOLIO 95
15.7.3 RECENT DEVELOPMENT 96
16 QUESTIONNAIRE 97
17 RELATED REPORTS 100